Inogen (INGN) Sets New 12-Month High and Low at $139.14

Inogen (NASDAQ:INGN) shares reached a new 52-week high and low on Friday . The company traded as low as $139.14 and last traded at $136.64, with a volume of 42529 shares trading hands. The stock had previously closed at $137.39.

A number of research analysts have weighed in on INGN shares. Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “buy” rating and set a $128.00 price objective on the stock in a research report on Tuesday, January 9th. BidaskClub upgraded shares of Inogen from a “hold” rating to a “buy” rating in a research report on Saturday, February 10th. Needham & Company LLC reiterated a “buy” rating and set a $150.00 price objective on shares of Inogen in a research report on Tuesday, March 27th. Finally, ValuEngine upgraded shares of Inogen from a “hold” rating to a “buy” rating in a research report on Friday, April 6th. Three analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $107.29.

How to Become a New Pot Stock Millionaire

The firm has a market capitalization of $2,838.83, a P/E ratio of 104.88, a PEG ratio of 3.72 and a beta of 1.03.

Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Tuesday, February 27th. The medical technology company reported $0.31 EPS for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.10. The firm had revenue of $63.79 million for the quarter, compared to analysts’ expectations of $62.01 million. Inogen had a net margin of 8.42% and a return on equity of 13.47%. research analysts expect that Inogen will post 1.6 earnings per share for the current fiscal year.

In other news, EVP Alison Bauerlein sold 15,911 shares of the company’s stock in a transaction dated Thursday, March 8th. The shares were sold at an average price of $124.48, for a total value of $1,980,601.28. Following the transaction, the executive vice president now directly owns 20,072 shares in the company, valued at $2,498,562.56. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Matt Scribner sold 2,500 shares of the company’s stock in a transaction dated Thursday, March 15th. The stock was sold at an average price of $127.95, for a total transaction of $319,875.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 158,369 shares of company stock worth $18,919,065. Company insiders own 5.29% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. grew its holdings in Inogen by 4.0% during the 4th quarter. BlackRock Inc. now owns 2,306,534 shares of the medical technology company’s stock worth $274,662,000 after acquiring an additional 87,737 shares in the last quarter. Brown Capital Management LLC grew its holdings in Inogen by 1.8% during the 4th quarter. Brown Capital Management LLC now owns 2,260,706 shares of the medical technology company’s stock worth $269,205,000 after acquiring an additional 40,994 shares in the last quarter. Rockefeller Financial Services Inc. grew its holdings in Inogen by 0.9% during the 4th quarter. Rockefeller Financial Services Inc. now owns 301,499 shares of the medical technology company’s stock worth $35,903,000 after acquiring an additional 2,729 shares in the last quarter. Wells Fargo & Company MN grew its holdings in Inogen by 15.7% during the 3rd quarter. Wells Fargo & Company MN now owns 300,025 shares of the medical technology company’s stock worth $28,533,000 after acquiring an additional 40,798 shares in the last quarter. Finally, Fred Alger Management Inc. grew its holdings in Inogen by 7.9% during the 4th quarter. Fred Alger Management Inc. now owns 248,232 shares of the medical technology company’s stock worth $29,559,000 after acquiring an additional 18,269 shares in the last quarter. Hedge funds and other institutional investors own 98.93% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/13/inogen-ingn-sets-new-12-month-high-and-low-at-139-14.html.

About Inogen

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply